Advanced technology platforms optimize the efficiencies and sustainability of single-use bioreactors, setting the scene for the next evolutionary step in biomanufacturing.
Chris Chen
Advertisement
Chris Chen is the CEO of WuXi Biologics. Dr Chen served on the International Board of Directors for ISPE and holds a PhD in Chemical Engineering from the University of Delaware.
Articles by Chris Chen
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Report - Digital Transformation in Biopharma: The Gap Between Hype and Implementation
2
Reducing CAR-T Manufacturing Times and Cost: Q&A with Trenchant’s Jon Ellis
3
How Big Biopharma Investment in CGTs Will Redefine the Industry Pipeline
4
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
5
